• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于女性膀胱过度活动症的抗胆碱能药物的依从性、持久性和转换率:来自挪威处方数据库的数据。

Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.

机构信息

Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway.

出版信息

Acta Obstet Gynecol Scand. 2013 Oct;92(10):1208-15. doi: 10.1111/aogs.12196. Epub 2013 Jul 11.

DOI:10.1111/aogs.12196
PMID:23763552
Abstract

OBJECTIVE

To investigate the pattern of use of anticholinergic drugs for overactive bladder among women in Norway with regard to persistence, adherence and switch rates.

DESIGN

Observational study.

SETTING AND SAMPLE

Data from the Norwegian Prescription Database on prescriptions for tolterodine, solifenacin, darifenacin and fesoterodine filled in Norwegian pharmacies from 1 January 2004 to 31 December 2010.

METHODS AND MAIN OUTCOME MEASURES

Data from the database were analysed at an individual level, and drug persistence, discontinuation rates and switch rates during a follow-up period of 365 days after the first prescription were calculated.

RESULTS

Overall 1-year persistence for new users was 38.0%. Within the same period, a total of 10.3% switched from the index drug to another drug in the same group, whereas 51.7% discontinued without switching. Users of solifenacin and tolterodine were somewhat more persistent than users of darifenacin and fesoterodine. Persistence was lowest (20.9%) in the age group 18-39 years, increased with age and was highest in the age groups 70-79 years and 80 years and above (43.5 and 43.3%, respectively). In total, 31.9% filled only one prescription of the drug and, of these, only one of four women switched to another drug. The proportion who were adherent during treatment was 60.4%.

CONCLUSIONS

The discontinuation rate for anticholinergic drugs for overactive bladder in women is high. The reasons why patients stop using them remain obscure but could be related both to a limited clinical effect and an unacceptable adverse effect burden.

摘要

目的

调查挪威女性中抗胆碱能药物治疗膀胱过度活动症的使用模式,包括持续性、依从性和转换率。

设计

观察性研究。

设置和样本

数据来自挪威处方数据库,包括 2004 年 1 月 1 日至 2010 年 12 月 31 日期间在挪威药店开具的托特罗定、索利那新、达非那新和非索罗定处方。

方法和主要观察指标

对数据库中的个体数据进行分析,计算首次处方后 365 天的药物持续性、停药率和转换率。

结果

新使用者的 1 年总体持续性为 38.0%。同期,共有 10.3%的患者从索引药物转换为同一组中的另一种药物,而 51.7%的患者未转换即停药。与达非那新和非索罗定相比,索利那新和托特罗定的使用者具有更高的持续性。18-39 岁年龄组的持续性最低(20.9%),随着年龄的增长而增加,70-79 岁和 80 岁及以上年龄组的持续性最高(分别为 43.5%和 43.3%)。总体而言,31.9%的患者仅开具了一种药物的处方,其中只有四分之一的女性转换为另一种药物。治疗期间依从性的比例为 60.4%。

结论

女性使用抗胆碱能药物治疗膀胱过度活动症的停药率较高。患者停止使用这些药物的原因尚不清楚,但可能与有限的临床疗效和不可接受的不良反应负担有关。

相似文献

1
Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.用于女性膀胱过度活动症的抗胆碱能药物的依从性、持久性和转换率:来自挪威处方数据库的数据。
Acta Obstet Gynecol Scand. 2013 Oct;92(10):1208-15. doi: 10.1111/aogs.12196. Epub 2013 Jul 11.
2
Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.长期使用抗胆碱能药物治疗膀胱过度活动症的模式和治疗失败。
Clin Ther. 2013 Nov;35(11):1744-51. doi: 10.1016/j.clinthera.2013.08.017. Epub 2013 Oct 3.
3
Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.将托特罗定换用其他新型抗毒蕈碱药物治疗对患者的益处。
Actas Urol Esp. 2014 Apr;38(3):156-63. doi: 10.1016/j.acuro.2013.07.008. Epub 2013 Oct 8.
4
Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study.瑞典抗胆碱能药物用于治疗膀胱过度活动症:一项全国性药物流行病学研究。
Int Urogynecol J Pelvic Floor Dysfunct. 2009 Nov;20(11):1285-91. doi: 10.1007/s00192-009-0957-z. Epub 2009 Jul 28.
5
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.索利那新在曾接受4毫克托特罗定缓释制剂治疗的患者中的疗效:一项为期12周的多中心、开放标签、灵活剂量研究的结果。
Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.
6
Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.索利那新与托特罗定治疗女性膀胱过度活动症的尿动力学效应、治疗效果及安全性比较
J Obstet Gynaecol Res. 2011 Aug;37(8):1084-91. doi: 10.1111/j.1447-0756.2010.01493.x. Epub 2011 Apr 19.
7
Update on drugs for overactive bladder syndrome.膀胱过度活动症药物的最新进展。
Drug Ther Bull. 2007 Jun;45(6):44-8. doi: 10.1136/dtb.2007.45644.
8
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.在英国国家医疗服务体系中,索利那新与非索罗定、奥昔布宁速释制剂、丙哌维林、托特罗定缓释制剂和托特罗定速释制剂治疗膀胱过度活动症患者的成本效益比较。
BJU Int. 2010 Aug;106(4):506-14. doi: 10.1111/j.1464-410X.2009.09160.x. Epub 2010 Feb 3.
9
Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.非索罗定与托特罗定缓释片治疗膀胱过度活动症的疗效比较:男女患者的疗效比较。
BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.
10
Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.坚持使用处方抗毒蕈碱药物治疗膀胱过度活动症:英国经验。
BJU Int. 2012 Dec;110(11):1767-74. doi: 10.1111/j.1464-410X.2012.11023.x. Epub 2012 Mar 12.

引用本文的文献

1
Comparisons of urinary bladder responses to common antimuscarinics reveals unique effects of darifenacin.膀胱对常用抗毒蕈碱药物反应的比较揭示了达非那新的独特作用。
Front Physiol. 2025 Feb 20;16:1534517. doi: 10.3389/fphys.2025.1534517. eCollection 2025.
2
Does the setting for intradetrusor onabotulinumtoxinA injection for management of overactive bladder matter?膀胱内注射A型肉毒毒素治疗膀胱过度活动症的注射环境重要吗?
Indian J Urol. 2024 Apr-Jun;40(2):101-106. doi: 10.4103/iju.iju_228_23. Epub 2024 Apr 1.
3
Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists.
泌尿科医生管理的膀胱过度活动症患者中索利那新治疗的规律和不规律使用情况及停药原因
Pharmaceuticals (Basel). 2024 Jan 16;17(1):116. doi: 10.3390/ph17010116.
4
Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review.抗胆碱能阶梯疗法治疗膀胱过度活动症时患者和临床医生面临的挑战:一项叙述性综述
Adv Ther. 2023 Nov;40(11):4741-4757. doi: 10.1007/s12325-023-02625-8. Epub 2023 Sep 19.
5
Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.骶神经调节治疗难治性膀胱过度活动症患者的中期疗效:单中心回顾性研究。
PLoS One. 2020 Jul 9;15(7):e0235961. doi: 10.1371/journal.pone.0235961. eCollection 2020.
6
Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.膀胱过度活动症(OAB)患者对口服抗毒蕈碱药物和米拉贝隆的真实世界持续性和依从性:一项系统文献综述
BMJ Open. 2018 Nov 21;8(11):e021889. doi: 10.1136/bmjopen-2018-021889.
7
Antimuscarinic use and discontinuation in an older adult population.老年人群中抗毒蕈碱药物的使用和停药情况。
Arch Gerontol Geriatr. 2019 Jan-Feb;80:1-11. doi: 10.1016/j.archger.2018.09.005. Epub 2018 Sep 22.
8
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.丹麦、瑞典和英国抗毒蕈碱药物治疗膀胱过度活动症的使用模式。
PLoS One. 2018 Sep 27;13(9):e0204456. doi: 10.1371/journal.pone.0204456. eCollection 2018.
9
Anticholinergic Drugs for Overactive Bladder in Frail Older Patients: The Case Against.抗胆碱能药物用于体弱老年患者的膀胱过度活动症:反对的理由
Drugs Aging. 2018 Sep;35(9):773-776. doi: 10.1007/s40266-018-0575-x.
10
Risk factors and factors affecting the severity of overactive bladder symptoms in Korean women who use public health centers.在使用公共卫生中心的韩国女性中,膀胱过度活动症症状的风险因素及影响其严重程度的因素。
Obstet Gynecol Sci. 2018 May;61(3):404-412. doi: 10.5468/ogs.2018.61.3.404. Epub 2018 May 8.